Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Restraining translation

Bantam's eIF4E inhibitors disrupt oncogene translation and cancer metabolism

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead compound will lead to a therapeutic more potent or safer than competing compounds in the same pathway.

mRNA translation begins with binding of a ribosome to the 5' end of an mRNA. This is facilitated by eukaryotic initiation factors including the eukaryotic translation initiation factor 4F (eIF4F) complex, which comprises three subunits: eIF4E

Read the full 897 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE